Rating On Watch: What To Expect After Capnia (NASDAQ:CAPN)’s Downgrade Rating From Maxim Group?

November 23, 2016 - By Dolores Ford

Rating On Watch: What To Expect After Capnia (NASDAQ:CAPN)'s Downgrade Rating From Maxim Group?

Capnia (NASDAQ:CAPN) Downgrade

Maxim Group gave Capnia (NASDAQ:CAPN) shares a new Hold rating in a an analyst report shared with investors and clients on Wednesday, 23 November. This is cut from the old Buy rating.

About 7,687 shares traded hands. Capnia Inc (NASDAQ:CAPN) has declined 24.22% since April 21, 2016 and is downtrending. It has underperformed by 29.55% the S&P500.

Capnia, Inc. is a healthcare company that develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The company has a market cap of $16.09 million. The Firm also has a therapeutics platform based on its technology for precision metering of gas flow. It currently has negative earnings. The Company’s first commercial product, CoSense End-Tidal Carbon Monoxide Monitor, aids in the detection of excessive hemolysis, a condition in which red blood cells degrade rapidly.

According to Zacks Investment Research, “Capnia, Inc. is focused on the development and commercialization of therapeutic and diagnostic products to address unmet healthcare needs. It develops diagnostics based on its proprietary Sensalyze (TM) technology for precision metering of gas flow. The Company’s lead product is CoSense (TM) which aids in the diagnosis of hemolysis. Capnia, Inc. is headquartered in Redwood City, California.”

CAPN Company Profile

Capnia, Inc., incorporated on August 25, 1999, is a healthcare firm that develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Firm also has a therapeutics platform based on its technology for precision metering of gas flow. The Company’s first commercial product, CoSense End-Tidal Carbon Monoxide (ETCO) Monitor, aids in the detection of excessive hemolysis, a condition in which red blood cells degrade rapidly. The Firm also develops and markets pulmonary resuscitation solutions for the inpatient and ambulatory neonatal markets. The Company, through its subsidiary NeoForce, Inc., offers NeoPip T-piece resuscitator and related consumable, which delivers pre-set inspiratory pressure and positive end-expiratory pressures. The Company’s other products include temperature probes, scales, surgical tables and patient surfaces.

More important recent Capnia Inc (NASDAQ:CAPN) news were published by: Reuters.com which released: “BRIEF-Capnia Inc reports Q3 loss per share $0.41” on November 14, 2016, also Globenewswire.com published article titled: “Capnia Acquires Neonatal Pulmonary Resuscitation Solutions From NeoForce Group …”, Prnewswire.com published: “Capnia, Inc. Announces Closing of Initial Public Offering and Partial Exercise …” on November 18, 2014. More interesting news about Capnia Inc (NASDAQ:CAPN) was released by: Quotes.Wsj.com and their article: “News Capnia Inc.CAPN” with publication date: August 13, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>